Fig. 4

Change from baseline in HAQ-DI scores and response rates. Change from baseline data in a HAQ-DI score and b HAQ-DI response rate^† by dactylitis location in patients with DSS > 0 at baseline; and c HAQ-DI score and d HAQ-DI response rate^†, in patients with DSS = 0 at baseline were pooled from OPAL Broaden and OPAL Beyond. *Comparisons where the 95% CI for tofacitinib does not overlap with the 95% CI for placebo. ^†Defined as ≥ 0.35-point decrease from baseline in HAQ-DI score. Dactylitis was defined as swelling of an entire digit; DSS ranged from 0 to 60 (60 = highest dactylitis severity) [20]. BID twice daily, CI confidence interval, DSS Dactylitis Severity Score, HAQ-DI Health Assessment Questionnaire-Disability Index, N total number of patients, n number of patients applicable for each category